1Department of Immunology, School of Medicine,UConn Health, 2Center for Molecular Discovery,University of New Mexico Health Sciences Center, 3Comprehensive Cancer Center,University of New Mexico Health Sciences Center, 4Department of Pathology,University of New Mexico Health Sciences Center, 5Autophagy, Inflammation, & Metabolism (AIM) Center,University of New Mexico
Denne protokol beskriver en flowcytometribaseret screeningsmetode med høj kapacitet til identifikation af småmolekylelægemidler, der hæmmer β2-integrinaktivering på humane neutrofiler.
